Topical corticosteroids play a key role in managing steroid-responsive dermatoses (SRD). Current topical corticosteroid therapies are associated with various disadvantages. This consensus article aims to provide a collation of evidence-based literature and clinical insights of the experts regarding the efficacy, safety and usage of clobetasol propionate (CP) 0.025% cream in the management of SRD such as plaque psoriasis. Clinical Evidence suggests that the novel formulation of CP 0.025% cream has comparable efficacy and a better safety profile compared with CP 0.05% cream in the management of plaque psoriasis.
According to the doctors' experience, CP 0.025% can be used as first-line treatment for the management of SRD. In children aged 12–18 years old, CP 0.025% may be used cautiously, considering the risk-benefit ratio. CP 0.025% may also be used as maintenance therapy after the disease is brought under control with systemic therapy. Using moisturisers, salicylic acid, calcipotriol or tacrolimus as concomitant therapy with CP 0.025% cream may be beneficial in the management of SRD. In various comorbidities such as diabetes and hypertension, CP 0.025% cream may be a better alternative compared with CP 0.05% cream. Clinical evidence and experts suggest that for management of SRD, clobetasol propionate 0.025% cream can be recommended as a formulation with comparable efficacy and better safety profile compared with CP 0.05% cream.